BIO-Europe® 2016: InflaRX CEO highlights pipeline goals
Neils Riedemann, founder and CEO of InflaRX, speaks to Lucie Ellis, senior writer at Scrip, about the company's pipeline candidates, upcoming development targets, and long-term goals. InflaRX is developing highly specific monoclonal antibodies targeting activation products of the complement system and has made breakthrough discoveries in anti-C5a antibody generation, resulting in a new class of antibodies. The company's anti-complement technology is the basis for a pipeline of new antibodies addressing a broad variety of inflammatory diseases. Lead product, IFX-1, is currently in Phase II for early septic organ dysfunction.